key: cord-0298124-k6ss6f6i
authors: Despuig, A.; Fonseca, K. L.; Habgood-Coote, D.; Del Rio-Alvarez, A.; Carrillo-Reixach, J.; Arias, L.; Gogichadze, N.; Goff, A.; Wildner, L. M.; Gogishvili, S.; Nikolaishvili, K.; Shubladze, N.; Avaliani, Z.; Cardona, P.-J.; Martinon-Torres, F.; Salas, A.; Gomez-Carballa, A.; Waddell, S. J.; Armengol, C.; Vashakidze, S.; Kaforou, M.; Vilaplana, C.
title: Unravelling the transcriptome of the human tuberculosis lesion and its clinical implications
date: 2022-04-03
journal: nan
DOI: 10.1101/2022.03.31.22273171
sha: 5aaf922bda3468796f18a3008f3ca68f7da8fe37
doc_id: 298124
cord_uid: k6ss6f6i

Tuberculosis (TB) disease causes up to 1.5 million deaths every year and represents an important problem of public health at worldwide level. Here, we quantified the gene expression signatures of granuloma biopsies across human TB pulmonary lesions, and validated the best gene candidates using NanoString technology, profiling 157 samples from 40 TB patients who underwent surgery. We characterised the transcriptional profile of the TB granuloma in comparison to healthy tissue, described an 11-gene signature and measured 7 proteins in plasma associated with it. We demonstrated a gradient of immune-related transcript abundance across the granuloma substructure and evidenced metabolically-active Mycobacterium tuberculosis in the lesions. Patients who converted to sputum negative after two months of starting treatment, showed enriched inflammatory pathways in the lesion several months after, supporting use of sputum culture conversion (SCC) as a prognostic biomarker during clinical management and as a factor to prioritise patients when considering lung surgery.

persistence of the bacilli within the lesion and does not reflect the health status of the patient 8 . Host blood RNA-derived biomarker signatures, especially those derived from RNA-Sequencing (RNA-Seq), have emerged as promising tools to overcome these limitations 9 . RNA signatures from patients with pulmonary TB, have shown potential in disease diagnosis and prognosis to monitor treatment efficacy and/or predict failure; they also show some correlation to the extent of lung pathology 9, 10 . However, literature regarding the RNA-Seq derived transcriptome of the human TB lesion biopsies is scarce 11 and host factors that drive cavitary lesion formation or trigger poor clinical outcomes remain unknown.

Based on the hypothesis that characterising human TB lesions at the transcriptomic level will drive novel biomarker and therapeutics research, we explored, quantified and validated the gene expression signatures of granuloma biopsies across a large collection of human TB pulmonary lesions and confirmed the best gene candidates using NanoString technology, profiling a total of 157 samples from 40 TB patients who underwent surgery.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint

We analysed total RNA from three different sections of the human TB granuloma from surgical biopsies (Central Lesion (CL), Internal Wall (IW), External Wall (EW)) and Pulmonary Nodules (PN). Additionally, healthy parenchyma (HT) from the same involved lung was collected as tissue control (Fig. 1a) . Patients were divided into a Discovery Set (14 patients Table 1 ).

The patients were matched according to sex and drug sensitivity of the Mtb isolate (Supplementary Table 2 ). The associations of the demographic, clinical and TB-related data of each participant in the Discovery Set at the time of surgery, and sex were assessed (Supplementary Table 3 ). Clinical and demographic features of the participants and removed TB lesions between Discovery and Validation Sets were also evaluated (Supplementary Table 4 ).

To identify genes differentially expressed between the TB granuloma and surrounding healthy lung tissue, we performed differential expression analysis between the granuloma (CL, IW, EW) and HT. We found a total of 6,056 significantly differentially expressed genes (DEGs). Of these, 3,405 genes were over-expressed in lung lesion tissues, whereas 2,651 were under-expressed compared to healthy lung tissue (Supplementary Data Set 1). The top 40 DEGs showed a clear separation between the granuloma samples and the HT samples (Fig.1b) . Only 10 granuloma-derived samples including 7 of the EW clustered with HT samples. This may reflect contamination with HT tissue due to the fact the HT is just adjacent to the EW, or could be justified by the well-accepted variability of granulomas within the same individual 12, 13 .

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint Next, we performed Gene-Set-Enrichment Analysis (GSEA) for the 6 and CXCL-10 being over-expressed and CD5L under-expressed in the granuloma compared with the healthy tissue.

To further evaluate if proteins encoded by the TB lesion 11-gene signature could mirror the ongoing tissue pathology in circulation, we studied further 7 secreted proteins corresponding to the genes. We used the pre-surgery plasma of whole cohort of 40 with . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint a poor prognosis requiring surgery, and compared the results with those from an independent cohort of patients who demonstrated better prognosis (completed anti-TB treatment (ATT)) and therefore, did not require surgery). Plasma levels of 5 out of 7 proteins expected to be induced (soluble CD14 (sCD14), MMP-9, CXCL-10, CCL19 and lactoferrin (LTF)) were significantly higher in patients requiring surgery, while CD5L levels were significantly lower as, as expected (Fig. 2c) . No statistical differences were found for MMP3 plasma levels. Our findings suggest that this 6-plasma protein TB signature may be clinically useful as marker of continued lung pathology after completion of antibiotic therapy, and should be further validated as circulating biomarkers of disease worsening and treatment failure.

Next, we compared the expression profiles derived from each section (CL, IW, and EW) against HT to characterise each granuloma tissue type in the TB lesion architecture. A total of 753 DEGs were common in all pairwise comparisons between the three lesion compartments vs HT, with CL vs HT having the highest number of unique DEGs (2,974) (Fig.3a) . The list of DEGs for the CL, IW and EW vs HT comparisons was constituted by 6,769, 4,712 and 867 genes respectively (Supplementary Data Sets 3, 4 and 5). The expression of genes associated with the different lesion compartments revealed an enrichment of over-expressed genes in the central lesion (Fig 3b) . Notably, the magnitude of differential expression decreased gradually towards the edge of the granuloma structures (Supplementary Data Set 6). As a Pulmonary Nodulus (PN) is often found near the primary lesion and were resected too, we also explored its molecular profile (Fig 1a) . The differential expression analysis between granuloma vs HT and PN . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 3, 2022. Next, we performed GSEA for the three sets of DEGs (CL vs HT, IW vs HT and EW vs HT), which revealed 34 Hallmark gene sets significantly enriched in the centre of TB lesion compared to the EW (Fig. 3c, Supplementary Data Set 8) . The most significant gene sets found to be enriched in CL vs EW were mainly related to an immune inflammatory response and complement ( Fig. 3c and d) , supporting the observation that changes found in granuloma vs HT were driven mainly by CL transcriptomic profile. Table 5 ). All seven genes followed a statistically significant descendant trend through the TB granuloma compartments towards healthy tissue (Fig.4) .

Next, we assessed if the presence of Mtb inside the lesions 14 could explain the inflammatory response found in the granuloma. RNA is produced by live bacilli, and therefore acts as a marker of metabolically active Mtb. We found evidence of Mtb ribosomal RNA transcripts in the RNA-Seq data of the lung lesion samples; therefore, we modified the Molecular Bacterial Load (MBL) assay measuring Mtb 16S rRNA transcripts 15 to detect and quantify Mtb in matched patient lung lesion. Eighteen of 27 patient lung lesions (66%) were positive for Mtb, with 16S rRNA abundance above the detection limit equivalent to 1.6x10 2 CFU (Fig. 5, Supplementary Figure 4 ). Mtb load ranged from 1.7x10 2 CFU to 2.0x10 4 CFU per lung sample. Furthermore, we stratified the patients considering Mtb drug sensitivity but no statistically significant differences were found. The data demonstrate live metabolically-active Mtb in two-thirds of the . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint patients despite prior anti tuberculosis drug therapy, which might explain the proinflammatory profile of the lesions.

A lung lesion gene expression signature differentiates fast and slow sputum culture

In order to get further insights into the gene expression of the TB lesion according to patient prognosis, we performed a supervised analysis comparing fast and slow SCC responders. The supervised analysis showed 950 significant DEGs ( Fig. 6a ; Supplementary Data Set 9). According to the GSEA analysis, two hallmark gene sets were significantly enriched in fast sputum converters, related to epithelial-mesenchymal transition and angiogenesis. The most significant gene sets found enriched in the TB lesion of slow sputum converters instead were related to interferon-gamma response and TNFalpha/NFKb signalling hallmarks ( Fig. 6b and c, Supplementary Data Set 10). While fast sputum converters show evidence of tissue remodelling, slow sputum converters exhibit a pro-inflammatory profile. Our data therefore suggest that an initial slow clearance of Mtb (> 2 months after the start of ATT) may be associated with greater lung inflammatory responses detected many months later (at 6 months after the start of ATT).

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 3, 2022.

Through RNA-Seq and NanoString nCounter technology, we have characterised a unique and large collection of 157 samples of TB lesions from 40 patients undergoing therapeutic surgery. One of the main strengths of the project is that fresh human TB lesion specimens (without formalin fixation or paraffin embedding) were transcriptionally characterised using two cutting-edge approaches in both Discovery and Validation participant cohorts. Although some variability was found between samples, we identified a clear pattern across all the patients, with a predominant pro-inflammatory transcriptional signature in TB lung lesion compared to the healthy tissue. As these patients are advanced TB cases with cavitary TB, who underwent lung resection surgery, the results may not be generalised to the whole spectrum of TB disease, which constitutes a limitation to the study. Nevertheless, our study included a larger number of samples in comparison to previous approaches and there are few papers published working on TB lung lesion, in total using 79 samples from 24 patients 13, 16, 17 . To our knowledge, this is the first study that has built and validated a transcriptional signature of a human TB granuloma from fresh TB lesion biopsy samples, using different granuloma compartments and including, not also MDR/XDR-TB patients as Dheda et al 11 , but also, DS-TB patients.

Here we show the important involvement of pro-inflammatory pathways in the TB human lesion, which is supported by Dheda's and Subbian's studies 11, 13 . Dheda et al described the pathways involved in different parts of cavitary lesions from 14 failed MDR-TB subjects that underwent surgery, pointing the cavity wall as the main source of pro-inflammatory activity 11 . In line with our findings and through ingenuity pathway analysis (IPA), they showed that pro-inflammatory pathways were especially overrepresented in the cavity wall, including nitric oxide production, reactive oxygen species, . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. technologies, some of the differentially expressed genes in the above-mentioned studies overlapped with our validated genes of interest. In contrast to Dheda's work, in our hands the centre of the TB lesion showed a more perturbed transcript abundance compared to the other lesion compartments. Additionally, we found a characteristic highly proinflammatory gene expression profile at the centre of the lesion, while the edges of the TB lesion cavities (EW) were more similar to healthy lung tissue. These differences in terms of spatial expression could be due to differences in the sample preparation or analyses, or to differences between the two patient cohorts.

The TB lesion 11-gene signature described here, predominantly encodes proteins related to the immune response, inflammatory processes, and cell signalling, such as LTB and MAP4K1 18, 19 , to orchestrate the antimycobacterial response. Some are already targets for host-directed therapies such as LTF, FCMR and CD5L 20-23 . In addition, CCL19 gene expression has been found to be increased in lungs post-infection in mice acting to induce lymphoid structures 24 . MMP-3 and MMP-9, as metalloproteinases, are known to participate in the orchestration of the TB granuloma 25,26 . It is also worth noting that MMP9, which has been suggested to be responsible for the persistence of cavities, was ranking among the top 10 DEG genes in the Subbian study 13 . In addition, IL2RG and CD14 were expressed in a similar pattern, unlike LTB. Similarly, LHFPL2, C1QB, and . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint HPSE genes from our spatial model of the TB granuloma also matched 13 . We found C1Q1 gene to be over-expressed in central parts of the granuloma, contributing for the proinflammatory profile. The expression of this gene has been highlighted as a disease severity biomarker 27 and linked to poor treatment response 28 . Finally, interleukin-2, CXCL-10, and soluble CD14 have been proposed as biomarkers of disease severity 29-31 .

Six proteins described as protein TB signature (sCD14, CD5L, CXCL-10, MMP-9, LTF and CCL19) were found statistically different in the plasma of patients ending up in surgery, in spite of completing treatment, compared to successfully treated TB patients.

Previously published blood microarray-derived signatures found up-regulated levels of is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint 6 months of treatment 35 . More recently they have also related both a larger burden of disease and a slower rate of reduction in scan metrics to delayed sputum conversion 36 .

The main novelty of our work is that our data showed that slow sputum converters have different transcriptional profiles in TB granulomas when compared to fast sputum converters, and this has clinical management implications. TB surgery is usually pursued in cases with persistent pulmonary cavities after long-term standard ATT despite successful sputum sterilisation. Achieving sputum conversion after two months of treatment has been associated with TB cavity persistence 7 . In our cohort, DS-TB/MDR-TB cases in the fast SCC converters was higher (5/8) than in slow converters (4/6), as previously described 37 . Although the SCC has been considered a surrogate of prognosis 38, 39 , it is still not used for clinical decision making. Importantly, our study suggests that patients who converted the sputum after two months still show inflammatory pathways enriched in the lesion after several months, while fast converters have enriched pathways involved in tissue repair. These data support using SCC at month 2 after starting treatment as a prognostic biomarker, and suggest it might be used as a factor to prioritise patients when considering lung surgery.

The TB lesion 11-gene signature of ongoing lung pathology, including the 6protein TB signature, should be further studied as potential biomarkers for performance evaluation, using larger cohorts including patients at different stages of disease. Our study is the first one showing evidences of metabolically-active bacilli in the lesions of two thirds of patients despite ATT, which may be the reason why these patients needed surgical intervention. We provide evidence that some circulating biomarkers mirror what is happening in situ in the lung, which may help for the development of new diagnostic and prognostic tools, and treatment strategies. Moreover, this is the first study showing different pulmonary transcriptomic patterns associated with sputum culture conversion . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint status, enabling the stratification of patients at an early timepoint in the clinical management of TB disease (month 2 after starting treatment) as part of a patient cantered approach to TB treatment.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint

This paper is part of the SH-TBL project (ClinicalTrials.gov Identifier: NCT02715271).

The protocol and research methodology, as well as associated documents (informed consent sheet, informed consent form) were reviewed and approved by both ethics' Written informed consent was obtained from all study participants before they were enrolled. Table 1 where total-RNA extraction was performed.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint Plasma samples from the same 40 patients were collected prior to surgery (SH-TBL Cohort) and kept frozen at -80ºC at the IGTP until further analysis. Samples used as controls in the biomarker analysis in plasma came from 13 patients from the ongoing STAGE-TB project (registered at the ClinicalTrials.gov database under the code NCT03691883) who had completed 6 months of ATT, and that were stored frozen at -80ºC in the IGTP facilities.

For an optimal RNA recovery, TB lesion biopsy samples were divided into 0. 16 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. 

The overall pipeline for the data handling, plotting and statistical analysis was conducted in R (v.3.6.2) 46 . After STAR mapping, a gene count data table was obtained including CL, IW, EW, PN, and HT samples belonging to the Discovery Set. Genes with mean raw counts that were below or equal to five were discarded as they were too lowly expressed . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint to be reliably quantified and could potentially interfere with the differential gene expression analysis.

The differential expression analysis from tissue count tables was conducted using the DESeq2 Bioconductor package (v.1.28.1) 47 . Genes were considered as significant DEGs when the Benjamini-Hochberg adjusted p-value was equal to or less than 0.05 (P ≤ 0.05).

The differential expression examination for two-factor levels under an experimental design was employed through the contrast argument. The contrast argument is the linear combination of the estimated log2FC, testing if differences between the groups were equal to zero. Patient's sex and drug-sensitivity type were accounted for in DESeq2 modelling. 

We used a statistical and a pathophysiological rationale to select the most meaningful Table 5 ). The pathophysiological rationale consisted of selecting the significant genes from each signature after running pre-ranked GSEA. Molecular pathways related to inflammatory processes, immune response, tissue remodeling, and destruction mechanisms as well as hypoxia and the complement system were prioritized for their role in the generation and maintenance of granulomatous lesions. We selected those genes with a FC >2.00/<-2.00 in the 6,056-gene human TB signature considering only the top DEG genes according to adjusted p-value.

To complete the genes of interest sub-set, we used a statistical rationale consisted of selecting those DEG genes that had a log2FC equal or superior to |1| as well as a per gene mean normalized count greater than 50 in all samples, considering only the top 20 significantly differentially expressed (DEG) ranked genes. From the 6,056-gene human TB granuloma signature, we selected MAP4K1, FCMR, and CCL19.

From the granuloma spatial analysis, we selected those genes whose log2 FC represents the entire gradient of expression, covering the genes mainly expressed in CL towards HT to be further validated. This was traduced into selecting the seven first DEG ranked genes . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. Finally, we were also interested in validating the expression of genes encoding circulating biomarkers related to prognostic features according to the literature and that were found DEG in the 6,056-human TB granuloma signature, namely IL2RG, CD14, CXCL10, CD5L, and MMP9, as they could be potentially related to the worsening phenotype of the SH-TBL Cohort.

In order to validate the RNA-Seq findings, we used a second patient set and an alternative Table 5 ), assayed using the NanoString platform.

A 27-probe set custom panel was designed and the Validation Set samples assayed using the NanoString nCounter XT assay, following manufacturer's instructions. We used the standard gene expression protocol for 12x RNA hybridization with 100 ng total-RNA as input, a hybridization time of 18h for all samples and mixing controls and TB samples in order to avoid any technical bias. Samples were analysed in a SPRINT nCounter system (NanoString). Raw counts were obtained and analysed through NanoString's nSolver (v.3.0) digital analyser software. Technical normalization was carried out using the geometric mean of the positive controls, whereas the background was established using . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint a threshold calculated by the mean of negative probes plus two standard deviations. We discarded those genes below the defined threshold. Differences in sample input were corrected by selecting the optimal number and best reference candidates from the set of HK genes included in the panel. GeNorm algorithm 50 implemented in the R package CrtlGene 51 was used to test not only the most stable reference genes but also the optimal number to carry out the normalization step. We disregarded HK candidate genes with less than 50 raw counts in any of the sample comparisons.

After obtaining the NanoString nCounter results, endogenous genes from the Validation Set were first analysed to determine statistical differences. We applied the Mann-Whitney U test to identify differentially expressed genes between groups, namely the pooled counts of granuloma and HT as well as between the sub-set of fast SCC and slow SCC. Biomarkers and Mtb RNA quantification data were analysed using GraphPad Prism (version 9.0). For circulating biomarker data, the Mann-Whitney test was used to compare two groups. Significant differences are as follows: *p ≤ 0.05, **p ≤ 0.01; ***p ≤ 0.001 and ****p ≤ 0.0001.

Mtb RNA was extracted from lung tissues using a modified GTC/TRIzol differential lysis extraction method 15 . Briefly, lesion tissue samples from 27 patients stored in RNALater (described above) were first disrupted in PBS using the gentleMACS Octo Dissociator H12.01 (Miltenyi Biotec) before adding 5M guanidine thiocyanate solution. The samples were centrifuged, passed through a 0.8 mm needle, and re-suspended in 1 mL TRIzol (Thermo Scientific). After bead beating with 0.1 mm silica beads (MP Biomedicals), RNA was DNase-treated and purified using the RNeasy Mini Kit (Qiagen) as previously described 52 . RNA yield and integrity were assessed using NanoDrop One (Thermo Scientific) and 2100 Bioanalyzer (Agilent Technologies).

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. In the present manuscript, we found CD5L under-expressed in the granuloma compared with the healthy tissue, as well as lower CD5L plasma levels in patients requiring surgery compared to those who didn't. Consequently, CD5L was included both in the TB lesion 11-gene signature and in the 6-plasma protein TB signature described in the present manuscript. C.V is an unpaid board member of the following non-profit organizations:

the FUITB foundation and the ACTMON foundation. Neither the ISCIII, the IGTP, the FUITB nor ACTMON have had any role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint

All metadata and sequencing data from this manuscript have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (GEO) Database and will be released after manuscript acceptance in a peer-reviewed scientific journal.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. ;  treatment response in clinical trials of novel antituberculosis agents. Lancet.

Infect. Dis. 7, 481-490 (2007) .

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. Correlation coefficient (R) and p-value (significant as p-value ≤ 0.05). c. Proteins encoded . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint by the TB granuloma set of genes were identified in plasma samples of TB patients whose underwent surgery (Surgery) and their levels compared to Non-surgery TB patients who had completed ATT (Non-surgery). Statistical analysis was performed with unpaired twotailed Mann-Whitney test. Biomarkers levels are represented on a log10-scale * refer to statistical differences between Non-surgery and Surgery patients' groups. *p < 0.05; **p< 0.01; ****p < 0.0001. Wallis test for multiple comparisons showing: * refer to statistical differences between the CL, IW or EW compartments when compared to HT; # refer to statistical differences between CL or IW compartments when compared to the EW. * ,# p <0.05; ** ## p <0.01; *** p <0.001; **** p <0.0001. Error bars represent +1 SD from three independent technical replicates. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. Figure 4 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 3, 2022. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. External Wall (EW) vs healthy tissue. Following a statistical and pathophysiological rationale, the genes better including the main pathophysiological features of the Discovery Set and the top-ranked genes from each signature were down-selected. In grey are represented the genes selected accordingly to a pathophysiological rationale after the GSEA analysis (pro-inflammatory and tissue remodeling gene sets); in black, the genes . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint selected according to a statistical rationale from the top 20 SDE genes (logFC >+1/-1, baseMean >50); in white, the genes encoding described circulant prognostic/diagnostic biomarkers with identified features in TB pathogenesis. The listed genes of interest derived from the two signatures were validated in Validation Set samples.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 3, 2022. ; https://doi.org/10.1101/2022.03.31.22273171 doi: medRxiv preprint

World TB Day 2022: Revamping and Reshaping Global TB Control Programs by Advancing Lessons learnt from the COVID-19 pandemic

WHO report on TB 2020. WHO

Surgical treatment of drug-resistant tuberculosis

Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis

Clinical pharmacology and lesion penetrating properties of second-and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis

Retrospective study of clinical and lesion characteristics of patients undergoing surgical treatment for Pulmonary Tuberculosis in Georgia

Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment Response

Host blood RNA signatures predict the outcome of tuberculosis treatment

Spatial network mapping of pulmonary multidrug-resistant tuberculosis cavities using RNA sequencing

The End of the Binary Era: Revisiting the Spectrum of Tuberculosis

Lesion-specific immune response in granulomas of patients with pulmonary tuberculosis: A pilot study

Genomic analyses of Mycobacterium tuberculosis from human lung resections reveal a high frequency of polyclonal infections

Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy

Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism

The immunoregulatory landscape of human tuberculosis granulomas

Expression of lymphotoxin-beta (LT-β) in chronic inflammatory conditions

A perspective on hpk1 as a novel immunooncology drug target

Blood and urine inducible protein 10 as potential markers of disease activity

Presepsin: A promising biomarker for the detection of bacterial infections

Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis Therapy

Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis

Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies therapeutic targets

Persisting PET-CT lesion activity and M. tuberculosis mRNA after pulmonary tuberculosis cure

Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies

Time to sputum culture conversion and its associated factors among multidrug-resistant tuberculosis patients in Eastern Africa: A systematic review and meta-analysis

Lilibeth Arias 1,2 , Nino Gogichadze 1,6 , Aaron Goff 7 , Leticia Muraro Wildner 7 , Shota Gogishvili 8 , Keti Nikolaishvili 8

Edifici Mar. Can Ruti Campus. Crtra. de Can Ruti, Camí de les Escoles, s/n. 08916, Badalona; Catalonia

Program of Predictive and Personalized Medicine of Cancer (PMPCC), Edifici Muntanya. Can Ruti Campus. Ctra. de Can Ruti

Maruashvili Str

Hospital Universitari Germans Trias i Pujol (HUGTIP)

Instituto de Investigación Sanitaria (IDIS)

Centre for Paediatrics and Child Health

Direcció Clínica Territorial de Malalties Infeccioses i Salut Internacional. Gerència territorial Metropolitana Nord, Institut Català de la Salut. Can Ruti Campus. Crtra. del Canyet, s/n. 08916, Badalona; Catalonia

The authors would like to thank the patients who agreed to participate in the study and the staff from the NCTLD who helped with the SH-TBL project. The authors also thank IL2RG Granuloma Healthy